RCT: CoronaVac showed efficacy of 83.5% for preventing symptomatic SARS-CoV-2 infection.

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey – The Lancet

Invited commentary: CoronaVac: more data for regulators and policy makers

Commentary on Twitter

NEW—Interim analysis from phase 3 trial suggests efficacy of 2 doses of #CoronaVac is 83.5% against symptomatic #COVID19. More research is needed to confirm efficacy in the long term, in a more diverse group, and against emerging #variants of concern.

? https://t.co/TN5b6wwclc pic.twitter.com/4zOvJFIIOH

— The Lancet (@TheLancet) July 8, 2021